Literature DB >> 15126995

Reduced bone mineral density and increased bone turnover in Prader-Willi syndrome compared with controls matched for sex and body mass index--a cross-sectional study.

Peter Vestergaard1, Kurt Kristensen, Jens M Bruun, John R Østergaard, Lene Heickendorff, Leif Mosekilde, Bjørn Richelsen.   

Abstract

OBJECTIVES: To study bone mineral status, body composition, and biochemical markers of bone turnover in Prader-Willi syndrome (PWS). STUDY
DESIGN: Eight subjects with PWS (three males, five females; mean age, 24 years [range 16-41]) were included. Each subject was compared with an age-, sex- and body mass index-matched control randomly drawn from the background population. Bone mineral density (BMD), lean body mass, and fat mass were measured. Plasma PINP, PIIINP, osteocalcin, total alkaline phosphatase, bone-specific alkaline phosphatase, C-terminal telopeptide of type I collagen, and urine cross-linked N-terminal telopeptide of type I collagen were measured as biochemical markers of bone and collagen turnover.
RESULTS: The PWS patients had significantly lower whole-body BMD (mean +/- SD, 1.020 +/- 0.041 vs 1.237 +/- 0.118 g/cm(2); 2p <.01) than controls due to lower bone mineral content (BMC: 2291 +/- 607 vs 2825 +/- 409 g; 2p=.02). Resorptive and formative bone markers were significantly elevated in patients compared with controls. Plasma testosterone was low in male patients (3.50 +/- 4.97 vs 19.2 +/- 8.78 nmol/L, 2p=.05), whereas no difference in plasma estradiol was present.
CONCLUSIONS: The patients had a low BMD due to a high bone turnover. This high turnover was probably linked to sex steroid deficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126995     DOI: 10.1016/j.jpeds.2004.01.056

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

1.  Comparison of whole genome linkage scans in premenopausal and postmenopausal women: no bone-loss-specific QTLs were implicated.

Authors:  H Yan; Y-J Liu; Q Zhou; P Xiao; R R Recker; H-W Deng
Journal:  Osteoporos Int       Date:  2008-09-03       Impact factor: 4.507

Review 2.  Review of Prader-Willi syndrome: the endocrine approach.

Authors:  Ryan Heksch; Manmohan Kamboj; Kathryn Anglin; Kathryn Obrynba
Journal:  Transl Pediatr       Date:  2017-10

3.  Prader-Willi syndrome: a single center's experience in Korea.

Authors:  Yea Ji Kim; Chong Kun Cheon
Journal:  Korean J Pediatr       Date:  2014-07-23

Review 4.  Prader- Willi syndrome: An uptodate on endocrine and metabolic complications.

Authors:  Giovanna Muscogiuri; Gloria Formoso; Gabriella Pugliese; Rosaria Maddalena Ruggeri; Elisabetta Scarano; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2019-06       Impact factor: 6.514

5.  Endocrine and Metabolic Illnesses in Young Adults with Prader-Willi Syndrome.

Authors:  Eu-Seon Noh; Min-Sun Kim; Chiwoo Kim; Kyeongman Jeon; Seonwoo Kim; Sung Yoon Cho; Dong-Kyu Jin
Journal:  J Pers Med       Date:  2022-05-25

6.  An update on the role of RANKL-RANK/osteoprotegerin and WNT-ß-catenin signaling pathways in pediatric diseases.

Authors:  Giacomina Brunetti; Gabriele D'Amato; Mariangela Chiarito; Apollonia Tullo; Graziana Colaianni; Silvia Colucci; Maria Grano; Maria Felicia Faienza
Journal:  World J Pediatr       Date:  2018-10-20       Impact factor: 2.764

7.  Anthropometric adjustments are helpful in the interpretation of BMD and BMC Z-scores of pediatric patients with Prader-Willi syndrome.

Authors:  T N Hangartner; D F Short; T Eldar-Geva; H J Hirsch; M Tiomkin; A Zimran; V Gross-Tsur
Journal:  Osteoporos Int       Date:  2016-07-04       Impact factor: 4.507

Review 8.  Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings.

Authors:  M A Angulo; M G Butler; M E Cataletto
Journal:  J Endocrinol Invest       Date:  2015-06-11       Impact factor: 4.256

9.  Endocrine manifestations and management of Prader-Willi syndrome.

Authors:  Jill E Emerick; Karen S Vogt
Journal:  Int J Pediatr Endocrinol       Date:  2013-08-21

Review 10.  Growth hormone therapy for Prader-willi syndrome: challenges and solutions.

Authors:  Graziano Grugni; Alessandro Sartorio; Antonino Crinò
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.